China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home

SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets